New recommendations for a thyroid and cardiovascular disease research agenda

New Rochelle, NY, May 13, 2019–New Recommendations for a Thyroid and Cardiovascular Disease Research Agenda have been co-published in Thyroid® and Circulation. The Guidelines are published online here in Thyroid®, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers and the official journal of the American Thyroid Association® (ATA®). The Guidelines are also copyrighted by the American Heart Association and are being simultaneously published in its journal Circulation.

“Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment,” presents the results of an international working group convened by the U.S. National Heart, Lung, and Blood Institute (NHLBI) responsible for developing research priorities relating thyroid dysfunction to the progression of cardiovascular disease. Led by Anne Cappola, MD, Perelman School of Medicine at the University of Pennsylvania (Philadelphia), coauthors included researchers from Brigham and Women’s Hospital (Boston, MA), Erasmus Medical Center (Rotterdam, The Netherlands), the National Heart, Lung, and Blood Institute (Bethesda, MD), New York University School of Medicine (New York), University of Arizona (Tucson), Johns Hopkins University School of Medicine (Baltimore, MD), University of Washington (Seattle), and Weill Cornell Medicine (New York, NY).

The expert scientists and clinicians discussed how thyroid function and thyroid therapy impact various aspects of cardiovascular disease, including arrhythmias, atherosclerosis, and heart failure. These discussions led to recommendations in three broad areas, including identification of novel biomarkers of thyroid action in cardiovascular tissues, defining subgroups of patients suitable for preventive and therapeutic approaches, and clinical trials involving thyroid medications that can improve cardiovascular performance and outcomes.

“The connection between thyroid and cardiac function has been intriguing physicians for more than a century. This multidisciplinary international working group convened by the NHLBI has identified key areas where further research may provide fundamental new insights into this connection, and these recommendations will be stimulating for numerous investigators interested in this field,” says Peter A. Kopp, MD, Editor-in-Chief of Thyroid®, Professor and Chief of the Division of Endocrinology, Diabetology and Metabolism at the University of Lausanne (Switzerland), and Professor of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine at Northwestern University Feinberg School of Medicine (Chicago, IL).

###

About the Journal

Thyroid, the official journal of the American Thyroid Association®, (ATA®) is an authoritative peer-reviewed journal published monthly online with open access options and in print. The Journal publishes original articles and timely reviews that reflect the rapidly advancing changes in our understanding of thyroid physiology and pathology, from the molecular biology of the cell to clinical management of thyroid disorders. Complete tables of content and a sample issue may be viewed on the Thyroid website. The complete Thyroid Journal Program includes the highly valued abstract and commentary publication Clinical Thyroidology®, led by Editor-in-Chief Angela Leung, MD and published monthly, and the groundbreaking videojournal companion VideoEndocrinology, led by Editor William Barry Inabnet, III, MD and published quarterly. Complete tables of content and sample issues may be viewed on the Thyroid website.

About the Society

The American Thyroid Association®, (ATA®) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international membership medical society with over 1,800 members from 43 countries around the world. Celebrating its 96th anniversary, the ATA delivers its mission — of being devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health — through several key endeavors: the publication of highly regarded professional journals, Thyroid®, Clinical Thyroidology®, and VideoEndocrinology; annual scientific meetings; research grant programs for young investigators, biennial clinical and research symposia; support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease and thyroid cancer. The ATA promotes thyroid awareness and information through its online Clinical Thyroidology® for the Public (distributed free of charge to over 11,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA website serves as the clinical resource for patients and the public who look for reliable information on the Internet.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Diabetes Technology & Therapeutics, Journal of Women’s Health, and Metabolic Syndrome and Related Disorders. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.